Synopsis
Synopsis
0
KDMF
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 441.4 g/mol |
---|---|
Molecular Formula | C19H19N7O6 |
XLogP3 | -1.1 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 9 |
Exact Mass | 441.13968135 g/mol |
Monoisotopic Mass | 441.13968135 g/mol |
Topological Polar Surface Area | 209 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 767 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Folic acid |
PubMed Health | Folic Acid |
Drug Classes | Nutriceutical, Nutritive Agent |
Drug Label | Folic acid, N-[p-[[(2-amino-4-hydroxy-6-pteridiny)methyl]amino]benzoyl]-L-glutamic acid, is a B complex vitamin containing a pteridine moiety linked by a methylene bridge to para-aminobenzoic acid, which is joined by a peptide linkage to glutamic aci... |
Active Ingredient | Folic acid |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | 1 mg; 1mg; 5mg/ml |
Market Status | Prescription |
Company | Bicon Pharm; Excellium; Jubilant Cadista; Cadila Pharms; Invagen Pharms; Hikma Pharms; Watson Labs; Amneal Pharm; Fresenius Kabi Usa; Vintage; Contract Pharmacal |
2 of 2 | |
---|---|
Drug Name | Folic acid |
PubMed Health | Folic Acid |
Drug Classes | Nutriceutical, Nutritive Agent |
Drug Label | Folic acid, N-[p-[[(2-amino-4-hydroxy-6-pteridiny)methyl]amino]benzoyl]-L-glutamic acid, is a B complex vitamin containing a pteridine moiety linked by a methylene bridge to para-aminobenzoic acid, which is joined by a peptide linkage to glutamic aci... |
Active Ingredient | Folic acid |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | 1 mg; 1mg; 5mg/ml |
Market Status | Prescription |
Company | Bicon Pharm; Excellium; Jubilant Cadista; Cadila Pharms; Invagen Pharms; Hikma Pharms; Watson Labs; Amneal Pharm; Fresenius Kabi Usa; Vintage; Contract Pharmacal |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
N-(4-Aminobenzoyl)-L-glutamic acid
CAS Number : 4271-30-1
End Use API : Folic Acid
About The Company : Further Pharmaceutical (www.further-pharm.com) is an innovation-driven and service-oriented biopharmaceutical company with global operations that develops and m...
2,4,5-Triamino-6-hydroxypyrimidine sulfate
CAS Number : 35011-47-3
End Use API : Folic Acid
About The Company : Further Pharmaceutical (www.further-pharm.com) is an innovation-driven and service-oriented biopharmaceutical company with global operations that develops and m...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
83
PharmaCompass offers a list of Folic Acid API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Folic Acid manufacturer or Folic Acid supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Folic Acid manufacturer or Folic Acid supplier.
PharmaCompass also assists you with knowing the Folic Acid API Price utilized in the formulation of products. Folic Acid API Price is not always fixed or binding as the Folic Acid Price is obtained through a variety of data sources. The Folic Acid Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pteroylmonoglutamic acid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pteroylmonoglutamic acid, including repackagers and relabelers. The FDA regulates Pteroylmonoglutamic acid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pteroylmonoglutamic acid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pteroylmonoglutamic acid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pteroylmonoglutamic acid supplier is an individual or a company that provides Pteroylmonoglutamic acid active pharmaceutical ingredient (API) or Pteroylmonoglutamic acid finished formulations upon request. The Pteroylmonoglutamic acid suppliers may include Pteroylmonoglutamic acid API manufacturers, exporters, distributors and traders.
click here to find a list of Pteroylmonoglutamic acid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pteroylmonoglutamic acid DMF (Drug Master File) is a document detailing the whole manufacturing process of Pteroylmonoglutamic acid active pharmaceutical ingredient (API) in detail. Different forms of Pteroylmonoglutamic acid DMFs exist exist since differing nations have different regulations, such as Pteroylmonoglutamic acid USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pteroylmonoglutamic acid DMF submitted to regulatory agencies in the US is known as a USDMF. Pteroylmonoglutamic acid USDMF includes data on Pteroylmonoglutamic acid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pteroylmonoglutamic acid USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pteroylmonoglutamic acid suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pteroylmonoglutamic acid Drug Master File in Japan (Pteroylmonoglutamic acid JDMF) empowers Pteroylmonoglutamic acid API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pteroylmonoglutamic acid JDMF during the approval evaluation for pharmaceutical products. At the time of Pteroylmonoglutamic acid JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pteroylmonoglutamic acid suppliers with JDMF on PharmaCompass.
A Pteroylmonoglutamic acid CEP of the European Pharmacopoeia monograph is often referred to as a Pteroylmonoglutamic acid Certificate of Suitability (COS). The purpose of a Pteroylmonoglutamic acid CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Pteroylmonoglutamic acid EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Pteroylmonoglutamic acid to their clients by showing that a Pteroylmonoglutamic acid CEP has been issued for it. The manufacturer submits a Pteroylmonoglutamic acid CEP (COS) as part of the market authorization procedure, and it takes on the role of a Pteroylmonoglutamic acid CEP holder for the record. Additionally, the data presented in the Pteroylmonoglutamic acid CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Pteroylmonoglutamic acid DMF.
A Pteroylmonoglutamic acid CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Pteroylmonoglutamic acid CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Pteroylmonoglutamic acid suppliers with CEP (COS) on PharmaCompass.
A Pteroylmonoglutamic acid written confirmation (Pteroylmonoglutamic acid WC) is an official document issued by a regulatory agency to a Pteroylmonoglutamic acid manufacturer, verifying that the manufacturing facility of a Pteroylmonoglutamic acid active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pteroylmonoglutamic acid APIs or Pteroylmonoglutamic acid finished pharmaceutical products to another nation, regulatory agencies frequently require a Pteroylmonoglutamic acid WC (written confirmation) as part of the regulatory process.
click here to find a list of Pteroylmonoglutamic acid suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pteroylmonoglutamic acid as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pteroylmonoglutamic acid API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pteroylmonoglutamic acid as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pteroylmonoglutamic acid and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pteroylmonoglutamic acid NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pteroylmonoglutamic acid suppliers with NDC on PharmaCompass.
Pteroylmonoglutamic acid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pteroylmonoglutamic acid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pteroylmonoglutamic acid GMP manufacturer or Pteroylmonoglutamic acid GMP API supplier for your needs.
A Pteroylmonoglutamic acid CoA (Certificate of Analysis) is a formal document that attests to Pteroylmonoglutamic acid's compliance with Pteroylmonoglutamic acid specifications and serves as a tool for batch-level quality control.
Pteroylmonoglutamic acid CoA mostly includes findings from lab analyses of a specific batch. For each Pteroylmonoglutamic acid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pteroylmonoglutamic acid may be tested according to a variety of international standards, such as European Pharmacopoeia (Pteroylmonoglutamic acid EP), Pteroylmonoglutamic acid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pteroylmonoglutamic acid USP).